MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
59.41
-0.22 (-0.37%)
At close: 4:00PM EDT

59.41 0.00 (0.00%)
After hours: 6:33PM EDT

Stock chart is not supported by your current browser
Previous Close59.63
Open59.82
Bid0.00 x 0
Ask0.00 x 0
Day's Range59.11 - 60.08
52 Week Range52.83 - 66.41
Volume13,500,074
Avg. Volume12,784,017
Market Cap159.974B
Beta1.11
PE Ratio (TTM)68.29
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.92 (3.22%)
Ex-Dividend Date2018-03-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Merck Gets Another Upgrade Thanks To Keytruda
    Investing.com2 days ago

    Merck Gets Another Upgrade Thanks To Keytruda

    Investing.com - Goldman Sachs (NYSE:GS) is the latest Wall Street firm to upgrade Merck (NYSE:MRK) because of the blockbuster potential of its cancer drug Keytruda.The firm upgraded Merck from neutral to buy, while adding it to its list of favorite stocks. In a note to clients, Morgan Stanley (NYSE:MS) said Keytruda sales, which doubled to $3.8 billion in 2017, could soar to $16 billion by 2025.Keytruda is widely expected to gain a larger share of the market for non-small cell lung cancers. It's currently approved for lung, skin and stomach cancers, and is being tested for still others. Morgan Stanley, Barclays (LON:BARC) and Leerick Partnters have all recently upgraded the stock and/or raised their price targets. Merck shares, however, are down 5% over the past 12 months.

  • Abbvie Up over 6% on 1Q18 Earnings Beat, Raised Earnings Forecast
    Market Realist7 hours ago

    Abbvie Up over 6% on 1Q18 Earnings Beat, Raised Earnings Forecast

    AbbVie (ABBV) released its 1Q18 earnings results for the quarter that ended on March 31 today. The company posted net revenues of $7.93 billion, representing YoY (year-over-year) revenue growth of ~21.4%. The reported revenue exceeded analysts’ estimates of $7.59 billion.

  • Bristol's Case for Opdivo Optimism Has Shaky Foundations
    Bloomberg9 hours ago

    Bristol's Case for Opdivo Optimism Has Shaky Foundations

    A lot has to go right for it to fend off Merck’s surging Keytruda.

  • How Analysts Rate JNJ after 1Q18 Earnings
    Market Realist13 hours ago

    How Analysts Rate JNJ after 1Q18 Earnings

    As discussed earlier, Johnson & Johnson reported a 12.6% increase in revenues to $20.0 million in 1Q18 as compared to $17.8 million in 1Q17. The increase included 8.4% growth in revenues at constant exchange rates and a 4.2% positive impact of foreign exchange.

  • Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates
    Market Realist13 hours ago

    Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates

    Bristol-Myers Squibb (BMY) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues in 1Q18. It reported EPS of $0.94 on revenues of $5.2 billion in 1Q18 today, compared to analysts’ estimates for EPS of $0.85 on revenues of $5.2 billion.

  • Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?
    Zacks14 hours ago

    Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?

    With both Merck and Pfizer are scheduled to report on May 1, this may be a good time to figure out which of these is a better stock.

  • What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?
    Market Realist14 hours ago

    What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?

    As discussed earlier, Johnson & Johnson (JNJ) reported revenue growth of 12.6% in its 1Q18 revenues to $20.0 billion.

  • Reutersyesterday

    U.S. court upholds dismissal of $200 mln Merck verdict against Gilead

    A U.S. appeals court on Wednesday affirmed a ruling that pharmaceutical company Merck & Co dishonestly obtained patent rights and was not entitled to collect a $200 million infringement verdict it won against rival Gilead Sciences Inc. The U.S. Court of Appeals for the Federal Circuit upheld a June 2016 ruling that the two Merck patents, which cover methods of treating Hepatitis C, were unenforceable because of a pattern of misconduct by the company, including lying under oath by one of its in-house lawyers.

  • Novartis Launches FocalView to Modernize Clinical Trials
    Market Realistyesterday

    Novartis Launches FocalView to Modernize Clinical Trials

    Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.

  • Analysts’ Estimates for Sanofi’s 1Q18 Earnings
    Market Realistyesterday

    Analysts’ Estimates for Sanofi’s 1Q18 Earnings

    Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.

  • Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?
    Market Realist2 days ago

    Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?

    Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.

  • How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
    Market Realist2 days ago

    How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?

    Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.

  • What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
    Market Realist2 days ago

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Headquartered in New York City, Bristol-Myers Squibb (BMY) is one of the leading American pharmaceutical companies. Bristol-Myers Squibb’s portfolio includes various cardiovascular products, neuroscience products, immunoscience products, oncology products, and virology products.

  • Why Incyte Stock Fell ~9% on April 24
    Market Realist2 days ago

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.

  • What's in the Cards for Merck (MRK) This Earnings Season?
    Zacks2 days ago

    What's in the Cards for Merck (MRK) This Earnings Season?

    Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.

  • Gilead Sciences Focuses on Its Liver Disease Portfolio
    Market Realist2 days ago

    Gilead Sciences Focuses on Its Liver Disease Portfolio

    By mid-2018, Gilead Sciences (GILD) expects its share of the HCV (hepatitis C) market, where it competes with AbbVie (ABBV), Merck (MRK), and Bristol-Myers Squibb (BMY), to stabilize. This stabilization is anticipated despite rapidly declining drug prices and reducing treatment duration due to new and better therapies. While the company is not expecting any disruptive product launches in the HCV segment in the next few years, it expects gradually declining patient numbers to affect revenue. Liver disease research programs

  • How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
    Market Realist2 days ago

    How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18

    About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.

  • Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
    Motley Fool3 days ago

    Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma

    It's a lot easier to be patient once those quarterly payments start adding up.

  • Henry Schein to Merge Animal Health with Vets First Choice
    Market Realist3 days ago

    Henry Schein to Merge Animal Health with Vets First Choice

    On April 23, Henry Schein (HSIC) announced its plans to spin off and merge its animal health business with Vets First Choice to form a joint venture, Vets First Corp., aimed to advance animal healthcare and benefit veterinarians, pets, product manufacturers, and pet owners. Henry Schein, one of the world’s largest global supply chain providers of animal health products, has established a top market position in North America, Europe, Australia, and New Zealand.

  • InvestorPlace3 days ago

    The Treasury Yield Is Trembling on the Edge of 3%

    U.S. equities finished near the unchanged line on Monday as investors braced for the beginning of a very busy week of earnings reports. And much attention is being paid in the rise in long-term interest rates, with the 10-year Treasury yield within millimeters of crossing the 3% threshold (2.998%).

  • Investopedia3 days ago

    Merck Shares Seen Rising 12% as Profits Jump

    Merck & Co. Inc.'s ( MRK) stock has had a rough three years with shares rising by a little more than 4%, versus an S&P 500 that has climbed by nearly 27%. The average price target on the stock is $67.68, nearly 12% higher than the stock's current price around $60.30. The chart shows a solid uptrend that has been in place for Merck since 2009—a decade-long uptrend.

  • Reuters3 days ago

    AstraZeneca flop a fresh blow to cancer immunotherapy combination

    The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study. Adding the company's experimental drug tremelimumab to its existing product Imfinzi failed to slow disease progression or extend life in patients who had already received at least two previous treatments, the drugmaker said on Tuesday.

  • Investopedia3 days ago

    AstraZeneca’s Lung Cancer Duo Flops

    AstraZeneca’s combo of the experimental drug tremelimumab and Imfinzi failed to slow disease progression or extend life for lung cancer patients

  • MarketWatch3 days ago

    Merck's stock surges to lead Dow's gainers after Goldman turns bullish

    Shares of Merck & Co. Inc. ran up $1.61, or 2.7%, to a near three-month high in afternoon trade Monday, enough to pace the Dow Jones Industrial Average's gainers, after Goldman Sachs turned bullish on ...